David Wainer is a columnist for The Wall Street Journal and Yahoo Finance. He specializes in writing about the intersection of finance, healthcare, and biotechnology, providing insights into investment trends and market analysis. His work has also been featured in JD Supra.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
David Wainer's coverage predominantly focuses on investment analysis within the healthcare and pharmaceutical sectors. His articles encompass a range of topics, including stocks, biotech, and investing in relation to developments within these industries.
Given his focus on investment analysis and citation of data, David would likely be interested in receiving pitches from experts who can provide insightful perspectives backed by data related to healthcare and pharmaceutical companies' performance or industry trends. Additionally, professionals with expertise in financial analysis specific to the healthcare sector may find success when reaching out to him.
Considering his concentration on the international market rather than a specific geographic area, sources providing global insights into healthcare investments and pharmaceutical developments could capture his attention effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The next few months will be crucial for obesity players Eli Lilly, Novo Nordisk and Amgen.
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but investors in vaccine stocks are already taking cover. Donald Trump said on Tuesday that Kennedy, an anti-vaccine activist, could “do pretty much what he wants” in his administration. In a video posted last week, Kennedy said that Trump had “promised” him control of several health-focused governmental offices, including Health and Human Services.
Few would think professional sports leagues and the drug-development industry have much in common. When it comes to building up a pipeline, though, there is a striking similarity with valuable insights for executives on the prowl for deals. The news sent Bristol-Myers Squibb which recently won approval for a rival schizophrenia treatment, surging 10.5%.
Donald Trump’s nomination of vaccine-skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services is sending shockwaves throughout the broader pharma industry, beyond vaccine makers such as Moderna and Pfizer. One area of heightened focus is the fast-growing market for obesity and diabetes drugs like Mounjaro and Ozempic. Eli Lilly and Novo Nordisk are seeking to broaden insurance coverage for such drugs and are conducting studies to show that the benefits extend beyond weight loss to conditions such as cardiovascular disease and sleep apnea.
By: David Wainer
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ramp up production enough.
By: David Wainer
The vaccine skeptic may find it hard to enact earth-shattering changes to American healthcare
By: David Wainer
Hospitals account for about 30% of the $4.5 trillion the U.S. spends annually on healthcare, compared with 9% for drugs. While pharmaceutical companies and insurers often take political heat, hospitals could become a target for a Republican administration looking to curb spending.
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
The UnitedHealthcare CEO shooting has sharpened the public’s focus on the role of private insurers, a necessary evil in the U.S. healthcare system.
Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.
(833) 317-6278 
